Aushon Pharmaceuticals: Approval Notice for the Market Application of Imatinib Mesylate Obtained Chemical Raw Materials

Sina Finance reported on March 31 that Aoxiang Pharmaceutical announced on March 31 that the company has received the "Notice of Approval of Chemical Raw Materials Market Application" for the approval and issuance of the raw material for Lenvatinib phosphate by the National Medical Products Administration. Lenvatinib phosphate is used to treat splenomegaly and related symptoms in adult patients with primary myelofibrosis at intermediate or high risk, secondary myelofibrosis from polycythemia vera, and myelofibrosis from essential thrombocythemia.